| Russellville Physicians Llc | |
|
15225 Highway 43 Russellville AL 35653-1999 | |
| (256) 331-1900 | |
| (256) 331-1901 |
| Full Name | Russellville Physicians Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 15225 Highway 43, Russellville, Alabama |
| Authorized Official Name and Position | Steve Clapp (PRESIDENT) |
| Authorized Official Contact | 8652694074 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Russellville Physicians Llc 15225 Highway 43 Russellville AL 35653-1999 Ph: (256) 331-1900 | Russellville Physicians Llc 15225 Highway 43 Russellville AL 35653-1999 Ph: (256) 331-1900 |
| NPI Number | 1669861662 |
|---|---|
| Provider Enumeration Date | 01/13/2015 |
| Last Update Date | 01/13/2015 |
| Medicare PECOS PAC ID | 6507187044 |
|---|---|
| Medicare Enrollment ID | O20150609001012 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.
The London School of Hygiene & Tropical Medicine (LSHTM) will play a key role in a new Centre for Care that will support reform within the care system by providing research and evidence that can guide decision making and practice.
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669861662 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | John R Almirol |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1598705816 PECOS PAC ID: 3274622378 Enrollment ID: I20071127000494 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.
The London School of Hygiene & Tropical Medicine (LSHTM) will play a key role in a new Centre for Care that will support reform within the care system by providing research and evidence that can guide decision making and practice.
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
› Verified 6 days ago
| Provider Name | Shawn A Watts |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1639358864 PECOS PAC ID: 3870763949 Enrollment ID: I20110826000722 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.
The London School of Hygiene & Tropical Medicine (LSHTM) will play a key role in a new Centre for Care that will support reform within the care system by providing research and evidence that can guide decision making and practice.
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
› Verified 6 days ago
| Provider Name | Ram Sapkota |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1205013638 PECOS PAC ID: 4789737941 Enrollment ID: I20111117000218 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.
The London School of Hygiene & Tropical Medicine (LSHTM) will play a key role in a new Centre for Care that will support reform within the care system by providing research and evidence that can guide decision making and practice.
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
› Verified 6 days ago
| Provider Name | Chenyi J Chenyi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922387299 PECOS PAC ID: 2264651561 Enrollment ID: I20140918002190 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.
The London School of Hygiene & Tropical Medicine (LSHTM) will play a key role in a new Centre for Care that will support reform within the care system by providing research and evidence that can guide decision making and practice.
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
› Verified 6 days ago
| Provider Name | Phillip Jordan Dean |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1245464114 PECOS PAC ID: 2264754548 Enrollment ID: I20150722006032 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.
The London School of Hygiene & Tropical Medicine (LSHTM) will play a key role in a new Centre for Care that will support reform within the care system by providing research and evidence that can guide decision making and practice.
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
› Verified 6 days ago
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.
The London School of Hygiene & Tropical Medicine (LSHTM) will play a key role in a new Centre for Care that will support reform within the care system by providing research and evidence that can guide decision making and practice.
A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.
› Verified 6 days ago
Russellville Hospital Medical Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 15225 Highway 43 Ste I, Russellville, AL 35653 Phone: 256-331-2700 Fax: 256-331-2777 | |
Lakeland Cardiology & Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 531 Gandy St Ne, Russellville, AL 35653 Phone: 205-485-7280 Fax: 205-485-7391 | |
Russellville Internal Medicine Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 535 Gandy St Ne, Russellville, AL 35653 Phone: 256-332-1120 Fax: 256-332-1198 | |
Almirol Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15225 Highway 43, Suite G, Russellville, AL 35653 Phone: 256-331-1900 Fax: 256-331-1901 | |
John R Almirol M.d. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 Jackson Ave S, Russellville, AL 35653 Phone: 256-332-3321 Fax: 256-331-0720 | |
Dba Lakeshore Pediatric Rural Health Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 603 Gandy St Ne, Russellville, AL 35653 Phone: 256-331-5055 Fax: 256-460-4647 | |
Family Medicine Of Russellville Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 605 Gandy St Ne, Russellville, AL 35653 Phone: 256-332-8969 Fax: 256-332-8353 |